AbbVie dividend
AbbVie’s latest declared quarterly dividend is $1.73 per share; the forecast’s base case rises from $7.19 to $7.91 annually, while the bear case holds $6.92. AbbVie paid $11,657 million in dividends in 2025, while its cash engine remained powerful despite stock compensation and acquisitions.
How much does AbbVie pay in dividends per share?
The dividend base case rises from $7.19 to $7.91 per share as quarterly payments increase. The bear case holds the annual amount at $6.92, despite AbbVie’s long record of increases. The bull case reaches $8.34 because stronger cash generation permits larger raises, while acquisition spending and debt make that outcome less likely.
| October 2027 | October 2028 | October 2029 | |
|---|---|---|---|
| Earnings | 29,200 (29,127 / 30,000) | 32,390 (27,913 / 35,280) | 35,700 (26,640 / 40,420) |
| Shares (millions) | 1,767 (1,768 / 1,766) | 1,767 (1,769 / 1,765) | 1,767 (1,770 / 1,764) |
| Dividends per share | 7.19 (6.92 / 7.28) | 7.55 (6.92 / 7.79) | 7.91 (6.92 / 8.34) |
| Price to earnings | 17.54 (14.28 / 19.13) | 16.90 (13.62 / 18.51) | 16.09 (13.29 / 18.55) |
Does AbbVie’s cash cover its dividend?
The company’s operating medicines generated substantial free cash flow. The calculation used here subtracts stock compensation, because shares given to employees dilute existing owners even though they do not require an immediate cash payment. AbbVie recorded $955 million of stock-based compensation in 2025 and received $172 million when employees exercised options.
Dividends and acquisitions narrow the remaining choice further. AbbVie paid $11,657 million in dividends in 2025, while external acquisitions and investments also used cash. The cash engine is powerful, but conventional free cash flow is not the same as cash available to reduce debt or buy the next medicine.
| Year to Dec 2025 | Year to Dec 2024 | Year to Dec 2023 | Year to Dec 2022 | Year to Dec 2021 | |
|---|---|---|---|---|---|
| Real free cash flow (after stock pay) (calculated) | 16,861 | 16,921 | 21,315 | 23,577 | 21,298 |
| Dividends paid | 11,657 | 11,025 | 10,539 | 10,043 | 9,261 |
| Shares bought back | 980 | 1,708 | 1,972 | 1,487 | 934 |
| Acquisitions | 204 | 17,493 | 0 | 255 | 525 |
| New shares sold | 172 | 214 | 180 | 262 | 244 |
| Returned to shareholders, share of real free cash flow (calculated) | 74.9% | 75.2% | 58.7% | 48.9% | 47.9% |
What could change AbbVie’s dividend?
Dividends are forecast separately and added to the stated returns. The latest declared quarterly rate is $1.73, while the board retains discretion over future payments.
What is AbbVie’s dividend yield at its share price?
The valuation snapshot implies about $16.41 of forecast EPS from a share price of $272.42 and a forward P/E of 16.6x. That implied figure sits above the latest 2026 adjusted-EPS guidance in the mid-$13 range, although the periods differ because the forward measure extends into 2027.
| Today (Oct 9, 2026) | |
|---|---|
| Share price | 272.42 |
| P/E, next 12 months (calculated) | 16.6x |
| Free cash flow yield (calculated) | 3.8% |
| Dividend yield (calculated) | 2.5% |